- Home
- SCZM vs SGP Comparison
SCZM vs SGP Comparison
Compare SCZM & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCZM | SGP |
|---|---|---|
| Founded | N/A | 2019 |
| Country | Canada | United States |
| Employees | 455 | 65 |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.2M | 650.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SCZM | SGP |
|---|---|---|
| Price | $8.42 | $25.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.00 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 395.4K | 97.2K |
| Earning Date | 05-29-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $79.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.61 | $17.06 |
| 52 Week High | $17.65 | $30.56 |
Technical Indicators
Market Signals| Indicator | SCZM | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 67.30 | 68.69 |
| Support Level | $5.95 | $20.95 |
| Resistance Level | $8.40 | $25.83 |
| Average True Range (ATR) | 0.42 | 1.34 |
| MACD | 0.22 | 0.38 |
| Stochastic Oscillator | 93.42 | 95.56 |
Price Performance
Historical ComparisonAbout SCZM Santacruz Silver Mining Ltd. Common Shares
Santacruz Silver Mining Ltd is engaged in the operation, acquisition, exploration, and development of mineral properties in Latin America, with a primary focus on silver and zinc, including lead and copper. The company earns the majority of its revenue from Zinc and Silver. The company's reportable operating segments are the Bolivar mine and processing plant, the Porco mine and processing plant, the Caballo Blanco Group, San Lucas, Zimapa mine and processing plant, and Corporate and Other activities. Key revenue is generated from Zimapan.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.